Evaluating Extracorporeal Shockwave Therapy for Men Aged 18 to 65 with Stable Peyronies Disease

What this Trial Is About

Researchers are evaluating the effectiveness of extracorporeal shock wave therapy in treating Peyronies disease, a condition affecting the penis. This single-center, prospective clinical trial focuses on patients diagnosed with stable stage Peyronies disease, meaning the condition has not worsened in pain or curvature for at least six months. The study is conducted by Uskudar University and aims to compare shock wave therapy with routine pharmacological treatment. Participants will be randomly assigned to one of two groups one receiving standard pharmacological treatment without special intervention, and the other undergoing Extracorporeal Shockwave Therapy. The therapy involves eight treatment sessions, each delivering 3000 pulses at 2.5 bar pressure and 15 Hz frequency twice a week using a radial shockwave device. The shock waves target the penile plaque area through gel application on the penile shaft. Before and after treatment, participants will complete assessments including the International Erectile Function Index-5 and the Quality of Life Questionnaire short form to evaluate erectile function and quality of life. These outcomes will be measured at 5 weeks. The study monitors adherence and collects data to statistically analyze the therapys impact on erectile function and quality of life over the study period.

Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease